Nonviral gene therapy targeting cardiovascular system

Area of Science:

• Cardiovascular Medicine
• Biotechnology
• Molecular Biology

Background:

• Gene therapy offers potential for treating ischemic diseases by inducing therapeutic angiogenesis.
• Effective gene delivery is crucial for successful gene therapy, with viral and nonviral vectors being key technologies.
• Nonviral gene delivery methods are gaining attention as safer alternatives to viral vectors.

Purpose of the Study:

• To review cellular and in vivo barriers in gene transfer.
• To provide an overview of chemical vectors and physical tools for nonviral cardiovascular gene transfer.
• To highlight advancements in gene delivery technologies for treating ischemic cardiovascular diseases.

Main Methods:

• Review of preclinical and clinical studies on gene therapy for angiogenesis.
• Analysis of viral and nonviral vector technologies, including cell-based gene transfer.
• Focus on physical approaches like ultrasonic microbubble gene delivery and chemical vectors.

Main Results:

• Ultrasonic microbubble gene delivery demonstrates a high safety profile, low cost, and repeatability.
• This physical approach enhances cell membrane permeability for plasmid DNA delivery.
• Nonviral strategies, including ultrasonic methods, show promise for cardiovascular gene therapy.

Conclusions:

• Gene therapy holds significant potential for treating ischemic cardiovascular diseases.
• Advancements in nonviral gene delivery vectors, particularly ultrasonic microbubble technology, are critical for improving therapeutic outcomes.
• Understanding and overcoming gene transfer barriers are essential for successful cardiovascular gene therapy.